1. Home
  2. BLX vs IMNM Comparison

BLX vs IMNM Comparison

Compare BLX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$43.11

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.69

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
IMNM
Founded
1977
2006
Country
Panama
United States
Employees
322
168
Industry
Commercial Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
2.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLX
IMNM
Price
$43.11
$19.69
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
139.8K
3.1M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
5.67%
N/A
EPS Growth
9.67
N/A
EPS
6.00
N/A
Revenue
$308,426,000.00
$9,679,000.00
Revenue This Year
$18.35
N/A
Revenue Next Year
$6.56
$11.53
P/E Ratio
$7.34
N/A
Revenue Growth
10.24
N/A
52 Week Low
$31.14
$5.15
52 Week High
$48.38
$25.30

Technical Indicators

Market Signals
Indicator
BLX
IMNM
Relative Strength Index (RSI) 36.68 46.91
Support Level $43.60 $21.00
Resistance Level $44.73 $21.67
Average True Range (ATR) 0.78 1.20
MACD -0.09 -0.37
Stochastic Oscillator 2.56 7.93

Price Performance

Historical Comparison
BLX
IMNM

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: